Published in Proc Soc Exp Biol Med on February 01, 1971
Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J Exp Med (1983) 2.80
Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med (1998) 2.65
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae. Infect Immun (1997) 2.27
Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun (1999) 2.20
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev (2011) 1.87
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis. Infect Immun (2006) 1.71
Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A (2006) 1.63
Interactions of C-reactive protein with the complement system. III. Complement-dependent passive hemolysis initiated by CRP. J Exp Med (1975) 1.48
Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology (2003) 1.33
Expression of C-reactive protein in the human respiratory tract. Infect Immun (2001) 1.31
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol (2008) 1.21
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J (2007) 1.19
Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. J Exp Med (1984) 1.17
Primary structure of human C-reactive protein. Proc Natl Acad Sci U S A (1977) 1.17
Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody. Infect Immun (1984) 1.16
The hepatitis E virus ORF3 protein modulates epidermal growth factor receptor trafficking, STAT3 translocation, and the acute-phase response. J Virol (2008) 1.15
Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae. Infect Immun (1985) 1.08
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta (2008) 1.06
Determination of antibodies to pneumococcal C polysaccharide in patients with community-acquired pneumonia. J Clin Microbiol (1985) 1.02
Binding of human C-reactive protein to bacteria. Infect Immun (1982) 1.02
Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding. Infect Immun (2005) 1.02
Hamster female protein. A new Pentraxin structurally and functionally similar to C-reactive protein and amyloid P component. J Exp Med (1981) 1.01
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol (2006) 1.01
C-reactive protein protects against preerythrocytic stages of malaria. Infect Immun (1989) 0.99
In vitro binding of human C-reactive protein by some pathogenic bacteria and zymosan. Clin Exp Immunol (1972) 0.98
Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun (2000) 0.97
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
Circulating human C-reactive protein binds very low density lipoproteins. Clin Exp Immunol (1984) 0.96
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J Immunol (2007) 0.95
In vivo turnover studies of C-reactive protein and lipoproteins in the rabbit. Clin Exp Immunol (1984) 0.94
Biomarkers in community-acquired pneumonia: a state-of-the-art review. Clinics (Sao Paulo) (2012) 0.94
Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J (2002) 0.94
Serum protein concentrations during Schistosoma mansoni infection in intact and T-cell deprived mice. I. The acute phase proteins, C3 and serum amyloid P-component (SAP). Immunology (1980) 0.93
Pentraxins and Fc receptors. Immunol Rev (2012) 0.92
Lymphocytes binding C-reactive protein during acute rheumatic fever. J Clin Invest (1978) 0.92
Isolation of a peptido-polysaccharide from the dermatophyte Epidermophyton floccosum and a study of its reaction with human C-reactive protein and a mouse anti-phosphorylcholine myeloma serum. Immunology (1977) 0.91
Effect of C-reactive protein on the complement-mediated stimulated of human neutrophils by Streptococcus pneumoniae serotypes 3 and 6. Infect Immun (1982) 0.91
Purification and characterization of excretory and secretory antigen of Toxocara canis larvae. Immunology (1983) 0.91
C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer. J Biol Chem (2009) 0.89
The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets (2008) 0.89
Isolation and characterization of guinea-pig serum amyloid P component. Immunology (1986) 0.88
Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L. Infect Immun (2000) 0.88
Cross-reactivity between C-reactive protein and idiotypic determinants on A phosphocholine-binding murine myeloma protein. J Exp Med (1981) 0.88
Atherosclerosis-related functions of C-reactive protein. Cardiovasc Hematol Disord Drug Targets (2010) 0.87
Comparative studies of serum and synovial fluid C reactive protein concentrations. Ann Rheum Dis (1987) 0.86
Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J Biol Chem (2011) 0.86
Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm (2014) 0.86
CRP and neutrophils: functional effects and complex uptake. Clin Exp Immunol (1986) 0.85
Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis. J Biol Chem (1992) 0.85
Identification and isolation of two pentraxins from bovine serum. Clin Exp Immunol (1987) 0.85
Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol (2016) 0.84
A Study of Association of Ankle Brachial Index (ABI) and the Highly Sensitive C - Reactive Protein (hsCRP) in Type 2 Diabetic Patients and in Normal Subjects. J Clin Diagn Res (2012) 0.84
C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J Virol (2013) 0.82
Research pointers: Association of common genetic variant with susceptibility to invasive pneumococcal disease. BMJ (2002) 0.82
Amino acid sequence homology between rat and human C-reactive protein. Biochem J (1984) 0.81
The phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of mice against pneumococcal infection. J Biol Chem (2012) 0.81
C-reactive protein is essential for innate resistance to pneumococcal infection. Immunology (2014) 0.80
Interactions of C-reactive protein and complement with liposomes. Proc Natl Acad Sci U S A (1977) 0.80
Choline Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New Antimicrobials. Antibiotics (Basel) (2016) 0.79
The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein. Immunology (1998) 0.79
Association of a single nucleotide polymorphism in the C-reactive protein gene (-286) with susceptibility to Plasmodium falciparum malaria. Mol Med (2009) 0.79
Overexpression of C-reactive Protein as a Poor Prognostic Marker of Resectable Hepatocellular Carcinomas. J Pathol Transl Med (2015) 0.79
Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J (2009) 0.79
C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms. Infect Immun (2015) 0.79
Aldosterone Receptor Antagonism Reduces Urinary C-Reactive Protein Excretion in Angiotensin II-Infused, Hypertensive Rats. J Am Soc Hypertens (2010) 0.79
Molecular correlates of spontaneous activity in non-human primates. J Neural Transm (Vienna) (2010) 0.78
Agglutination of intravenous lipid emulsion ('Intralipid') and plasma lipoproteins by C-reactive protein. Clin Exp Immunol (1986) 0.78
Regulated export of a secretory protein from the ER of the hepatocyte: a specific binding site retaining C-reactive protein within the ER is downregulated during the acute phase response. J Cell Biol (1992) 0.77
Binding of human C-reactive protein to monocytes: analysis by flow cytometry. Clin Exp Immunol (1991) 0.77
Phosphocholine-containing ligands direct CRP induction of M2 macrophage polarization independent of T cell polarization: Implication for chronic inflammatory states. Immun Inflamm Dis (2016) 0.77
Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin. Antimicrob Agents Chemother (2014) 0.76
Computational analysis of C-reactive protein for assessment of molecular dynamics and interaction properties. Cell Biochem Biophys (2013) 0.76
The Carbohydrate-linked Phosphorylcholine of the Parasitic Nematode Product ES-62 Modulates Complement Activation. J Biol Chem (2016) 0.76
Functional transformation of C-reactive protein by hydrogen peroxide. J Biol Chem (2017) 0.75
A novel protein, RafX, is important for common cell wall polysaccharide biosynthesis in Streptococcus pneumoniae: implications for bacterial virulence. J Bacteriol (2014) 0.75
Studies of the structure and binding properties of hamster female protein. Immunology (1993) 0.75
Restoration of suppressor function in athymic mice. Immunology (1978) 0.75
Pentraxins and IgA share a binding hot-spot on FcαRI. Protein Sci (2014) 0.75
The role of phosphate groups in the interaction of human C-reactive protein with galactan polysaccharides. Immunology (1986) 0.75
Impact of the glpQ2 gene on virulence in a Streptococcus pneumoniae serotype 19A sequence type 320 strain. Infect Immun (2014) 0.75
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA (1996) 9.45
Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet (1995) 4.31
Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J Clin Invest (1967) 4.31
Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science (1997) 3.92
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis (1974) 3.01
Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med (1977) 2.92
Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science (1991) 2.56
Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer (1974) 2.36
Malarial antibodies and autoantibodies to heart and other tissues in the immigrant and indigenous peoples of Uganda. Lancet (1968) 2.35
The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. Genes Dev (1995) 2.19
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17
Rabbit C1q: purification, functional and structural studies. J Immunol Methods (1972) 2.15
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Adipsin and complement factor D activity: an immune-related defect in obesity. Science (1989) 1.87
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 1.84
Autoimmunity to the heart in cardiac disease. Current concepts of the relation of autoimmunity to rheumatic fever, postcardiotomyand postinfarction syndromes and cardiomyopathies. Am J Cardiol (1969) 1.79
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis (1990) 1.75
Complement activation by C-reactive protein complexes. Ann N Y Acad Sci (1982) 1.75
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature (1979) 1.75
A QUANTITATIVE STUDY OF THE FIBRINOLYSIN-ANTIFIBRINOLYSIN REACTION. Science (1945) 1.74
Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans. J Am Acad Dermatol (1985) 1.71
Fatal adenovirus disease and human immunodeficiency virus infection. Pediatr Infect Dis J (1990) 1.69
Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol (1974) 1.68
Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by a commercial enzyme immunoassay. J Clin Microbiol (1986) 1.67
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet (1988) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A (2001) 1.59
Antibodies to mycobacteria in human tuberculosis. I. Development of antibodies before and after antimicrobial therapy. J Infect Dis (1980) 1.56
Demonstration of an antibody to proximal tubular antigen in the pathogenesis of experimental autoimmune nephrosis in rats. J Lab Clin Med (1969) 1.55
In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol (1987) 1.51
Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev Infect Dis (1984) 1.51
Cryptococcosis in a cancer hospital: clinical and pathological correlates in forty-six patients. Cancer (1977) 1.49
Characterization of murine BATF: a negative regulator of activator protein-1 activity in the thymus. Eur J Immunol (2001) 1.45
Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol (1997) 1.43
Immune complexes in congenital and natal cytomegalovirus infections of man. J Clin Invest (1977) 1.42
Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol (1987) 1.42
Clinical manifestations and therapy of Lactobacillus endocarditis: report of a case and review of the literature. Rev Infect Dis (1986) 1.41
Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol (2010) 1.40
Cross-reaction of group A streptococci and heart tissue: varying serologic specificity of cross-reactive antisera and relation to carrier-hapten specificity. Transplant Proc (1969) 1.39
IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol (2001) 1.39
Steroids for Pneumocystis carinii pneumonia and respiratory failure in the acquired immunodeficiency syndrome. A reassessment. Arch Intern Med (1990) 1.38
Chlamydia trachomatis in suburban adolescents. J Pediatr (1987) 1.36
Viridans streptococcal endocarditis: clinical, microbiological, and echocardiographic correlations. J Infect Dis (1986) 1.35
Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc Natl Acad Sci U S A (1991) 1.34
Stat4 regulates multiple components of IFN-gamma-inducing signaling pathways. J Immunol (2000) 1.33
Human factor D of the alternative complement pathway: purification and characterization. J Immunol (1977) 1.33
Autoantibodies to heart and rheumatic fever: the induction of autoimmunity to heart by streptococcal antigen cross-reactive with heart. Ann N Y Acad Sci (1965) 1.29
Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. Proc Natl Acad Sci U S A (1989) 1.29
Cutting edge: differential requirements for Stat4 in expression of glycosyltransferases responsible for selectin ligand formation in Th1 cells. J Immunol (2001) 1.28
Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen. J Clin Microbiol (1985) 1.28
Cutaneous nocardiosis. Case reports and review. J Am Acad Dermatol (1985) 1.28
Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med (1998) 1.22
Immunopathologic studies of systemic lupus erythematosus (SLE). I. Tissue-bound immunoglobulins in relation to serum antinuclear immunoglobulins in systemic lupus and in chronic liver disease with LE cell factor. J Clin Invest (1967) 1.22
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol (1981) 1.22
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Immune complexes and other laboratory features of pleural effusions: a comparison of rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Ann Intern Med (1980) 1.19
Modelling of the serine-proteinase fold by X-ray and neutron scattering and sedimentation analyses: occurrence of the fold in factor D of the complement system. Biochem J (1993) 1.19
C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res (1997) 1.18
Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol (1987) 1.17
Structure of human factor D. A complement system protein at 2.0 A resolution. J Mol Biol (1994) 1.17
Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice. J Biol Chem (1998) 1.17
Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity. J Mol Biol (1998) 1.16
The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol (1992) 1.16
Cutaneous infection at dog bite wounds associated with fulminant DF-2 septicemia. Am J Med (1985) 1.16
Cutting edge: differential expression of chemokines in Th1 and Th2 cells is dependent on Stat6 but not Stat4. J Immunol (2000) 1.15
The Arthus reaction in rodents: species-specific requirement of complement. J Immunol (2000) 1.14
The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression. J Immunol (2000) 1.13
Autoimmunity to heart and its relation to heart disease. Prog Allergy (1969) 1.13
Immune complex detection and complement activity in rheumatoid arthritis: a comparative study of a radioimmunoassay using monoclonal rheumatoid factor, gel diffusion techniques and C4 activity. Clin Exp Immunol (1978) 1.12
Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79. Public Health Rep (1984) 1.12
Comparison of two rapid culture methods for detection of cytomegalovirus in clinical specimens. J Clin Microbiol (1987) 1.10
Fall in human herpesvirus 6 seropositivity with age. Lancet (1988) 1.09
Translational regulation of complement protein C2 expression by differential utilization of the 5'-untranslated region of mRNA. J Biol Chem (1990) 1.09
Cytokine-stimulated T lymphocyte proliferation is regulated by p27Kip1. J Immunol (2000) 1.09
Stimulation of human neutrophil Fc receptor-mediated phagocytosis by a low molecular weight cytokine. J Immunol (1986) 1.09
C-reactive protein binding specificities: artificial and natural phospholipid bilayers. Ann N Y Acad Sci (1982) 1.08
Topology and structure of the C1q-binding site on C-reactive protein. J Immunol (2001) 1.08
"Nonspecific" stimulation of lymphocyte transformation by cellular fractions and acid extracts of group A streptococci. J Immunol (1971) 1.08
Rapid detection of influenza virus in cell culture by indirect immunoperoxidase staining with type-specific monoclonal antibodies. Diagn Microbiol Infect Dis (1987) 1.07
Cutaneous lesions in disseminated mucormycosis. JAMA (1973) 1.07
Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol (1992) 1.07
Structural basis of profactor D activation: from a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D. EMBO J (1999) 1.07
Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA (1988) 1.07
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07
Surface loops adjacent to the cation-binding site of the complement factor B von Willebrand factor type A module determine C3b binding specificity. Biochemistry (1997) 1.06
Opsonic properties of C-reactive protein. Stimulation by phorbol myristate acetate enables human neutrophils to phagocytize C-reactive protein-coated cells. J Immunol (1985) 1.06
In vitro biosynthesis of complement protein D by U937 cells. J Immunol (1985) 1.05
Age-related changes in serum immunoglobulins in patients with familial IgA deficiency and common variable immunodeficiency (CVID). Clin Exp Immunol (1997) 1.04
Molecular genetics, structure, and function of C-reactive protein. Immunol Res (1991) 1.04
Human complement proteins D, C2, and B. Active site mapping with peptide thioester substrates. J Biol Chem (1987) 1.04